Prosecution Insights
Prosecution Insights
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (33%) |
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOWLES, DAVID PAUL | 1 | 69.4% | +25.9% |
| OTTON, ALICIA L | 1 | 65.0% | +9.2% |
| YANG, JAY LEE | 1 | 73.9% | +2.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18273181 | Use Of Naturally Occurring Cyclic Peptides For Treatment Of SARS-COV-2 Infection | BOWLES, DAVID PAUL | 4d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18273181 | Use Of Naturally Occurring Cyclic Peptides For Treatment Of SARS-COV-2 Infection | BOWLES, DAVID PAUL | 4d overdue |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18273181 | Use Of Naturally Occurring Cyclic Peptides For Treatment Of SARS-COV-2 Infection | BOWLES, DAVID PAUL | 1654 | §102§103§112 | Non-Final OA | 4d overdue | Pending | Jul 19, 2023 |
| 18322243 | NIR-ABSORBING MATERIALS FOR OPTOELECTRONIC APPLICATIONS | OTTON, ALICIA L | 1699 | §102 | Non-Final OA | — | Pending | May 23, 2023 |
| 18312908 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | YANG, JAY LEE | — | §112 | Non-Final OA | — | Pending | May 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial